| Shareholder Update: Mill City Evaluating the Pharmaceutical Compounding Space | |
| | |
|
CALGARY, ALBERTA--(Marketwired - May 1, 2015) - MILL CITY GOLD CORP. ("Mill City" and/or the "Company") (TSX VENTURE:MC)(FRANKFURT:NJ6) is pleased to announce it is currently reviewing and evaluating a number of opportunities in the pharmaceutical compounding space. Pharmaceutical compounding ("Compounding") is a branch of pharmacy that continues to play a crucial role of drug development. Compounding is the creation of a particular pharmaceutical product to fit the unique need of a patient. To do this, compounding pharmacists combine or process appropriate ingredients using various tools. ON BEHALF OF THE BOARD OF DIRECTORS James R. Brown, Chairman, President & CEO The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
|
|
|
Mill City Gold Corp
|
|
EXPLORATION STAGE |
CODE : MC.V |
ISIN : CA5998052073 |
|
| |
ProfileMarket IndicatorsVALUE : Projects & res.Press releasesAnnual reportRISK : Asset profileContact Cpy |
Mill City Gold is a gold exploration company based in Canada. Mill City Gold holds various exploration projects in Canada. Its main exploration properties are SOUTHERN STAR EAGLE, CROXALL, NORTHERN STAR EAGLE and GP2 in Canada. Mill City Gold is listed in Canada and in United States of America. Its market capitalisation is CA$ 17.1 millions as of today (US$ 12.7 millions, € 11.2 millions). Its stock quote reached its highest recent level on November 05, 2010 at CA$ 1.87, and its lowest recent point on October 25, 2013 at CA$ 0.01. Mill City Gold has 89 939 000 shares outstanding. |